Last updated 45 days ago
Impact of NANO-PSO on Cognition in Older Adults with Mild to Moderate Cognitive Impairment
60 patients around the world
Available in Mexico
Distribuidora Biolife SA de CV
1Research sites
60Patients around the world
This study is for people with
Cognitive Impairment
Requirements for the patient
From 60 Years
All Gender
Medical requirements
- Patients attended at the Hospital Español.Patients of any gender who are 60 years or older.Patients presenting with mild to moderate cognitive impairment.Meet the diagnostic criteria for probable dementia of the National Institute on Aging and the Alzheimer's Association (NIA-AA) (2011).Meet the criteria for the typical variant of Alzheimer's disease, specifically a specific clinical phenotype.Progressive and gradual change in memory functions reported by the patient or the informant for at least 6 months.Objective evidence of a hippocampal-type amnesic syndrome, based on significant impairment in the performance of episodic memory tests with established specificity for AD.Subjects are primary and secondary school graduates and have the ability to complete cognitive capacity tests and other specified tests in the program.Total score on the Hachinski Ischemic Scale (HIS) ≤ 4.Patients who sign the informed consent.
- Patients with known allergy to any component of the NANO-PSO capsule (e.g., fish).Patients with short bowel syndrome, bariatric surgery, or gluten reaction that may affect intestinal absorption.Patients in palliative care with a life expectancy of less than 6 months according to the NECPAL scale.Patients with terminality criteria established in the comprehensive palliative care management guide of Mexico.
Sites
Hospital Español
Recruiting
StudyCOGMEG5
SponsorDistribuidora Biolife SA de CV
Study typeInterventional
Conditions
Cognitive Impairment
Requirements
From 60 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06520878
